The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Translational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Translational control of gene expression
Hannig, E. M. (2001) · BioEssays · doi:10.1002/bies.1108 · Cited by 1,189
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 1×
“The induction of p21 in these settings, unlike that for DNA damage, is required to facilitate the assembly of active cyclin D1/CDK4 complexes (Cheng et al., 1999; LaBaer et al., 1997).”
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
Self-citationMajumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Self-citationMammalian TOR: a homeostatic ATP sensor
Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S. C., & Thomas, G. (2001) · Science · doi:10.1126/science.1063518 · Cited by 962
Self-citationSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 923
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.
Gartel, A. L., & Tyner, A. L. (2002) · PubMed · Cited by 918
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889
Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C., & Thomas, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3112-3124.2004 · Cited by 742
Self-citationSeoane, J., Le, H.-V., & Massagué, J. (2002) · Nature · doi:10.1038/nature01119 · Cited by 684
Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair
Li, R., Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/371534a0 · Cited by 643
PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints
Keith, C. T., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.270.5233.50 · Cited by 518
Pathways governing G1/S transition and their response to DNA damage
Bartek, J., & Lukas, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02114-7 · Cited by 471
Myc pathways provoking cell suicide and cancer
Nilsson, J. A., & Cleveland, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207261 · Cited by 462
Targeting mTOR signaling for cancer therapy
Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 436
Rajasekhar, V. K., Viale, A., Socci, N. D., Wiedmann, M., Hu, X., & Holland, E. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00395-2 · Cited by 420
Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 404
Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T., & Miura, M. (1998) · Oncogene · doi:10.1038/sj.onc.1202021 · Cited by 350
The role of p53 in chemosensitivity and radiosensitivity
El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337
Proteasome-Mediated Degradation of p21 via N-Terminal Ubiquitinylation
Bloom, J., Amador, V., Bartolini, F., DeMartino, G., & Pagano, M. (2003) · Cell · doi:10.1016/s0092-8674(03)00755-4 · Cited by 322
Woods, D. B., & Vousden, K. H. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5141 · Cited by 319
Boulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O’Reilly, T., Stolz, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3554-2 · Cited by 318
Self-citationWu, S., Cetinkaya, C., Munoz-Alonso, M. J., von der Lehr, N., Bahram, F., Beuger, V., Eilers, M., Leon, J., & Larsson, L.-G. (2003) · Oncogene · doi:10.1038/sj.onc.1206145 · Cited by 317
Rapamycins: Mechanisms of Action and Cellular Resistance
Huang, S., Bjornsti, M.-A., & Houghton, P. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.3.360 · Cited by 287
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
Zhang, Y., Fujita, N., & Tsuruo, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202426 · Cited by 237
p21Waf1/Cip1 as a therapeutic target in breast and other cancers
Weiss, R. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00308-8 · Cited by 237
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1
Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K., & Suthanthiran, M. (2002) · Transplantation · doi:10.1097/00007890-200205270-00008 · Cited by 235
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
Huang, S., Shu, L., Dilling, M. B., Easton, J., Harwood, F. C., Ichijo, H., & Houghton, P. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00180-1 · Cited by 216
Gervais, J. L. M., Seth, P., & Zhang, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.19207 · Cited by 212
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
Panwalkar, A., Verstovsek, S., & Giles, F. J. (2004) · Cancer · doi:10.1002/cncr.20026 · Cited by 208
Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G., & Lamb, R. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.jcb.200206108 · Cited by 206
Self-citationLiu, Z.-M., Chen, G. G., Ng, E. K., Leung, W.-K., Sung, J. J., & Chung, S. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207173 · Cited by 167
Decker, T. W., Hipp, S., Ringshausen, I., Bogner, C., Oelsner, M., Schneller, F., & Peschel, C. (2002) · Blood · doi:10.1182/blood-2002-01-0189 · Cited by 159
Owa, T., Yoshino, H., Yoshimatsu, K., & Nagasu, T. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013371996 · Cited by 158
Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
Fan, S., Chang, J. K., Smith, M. L., Duba, D. E., Fornace, A. J., & O'Connor, P. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201052 · Cited by 150
Bross, L., Muramatsu, M., Kinoshita, K., Honjo, T., & Jacobs, H. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011749 · Cited by 145
Huang, S., Liu, L. N., Hosoi, H., Dilling, M. B., Shikata, T., & Houghton, P. J. (2001) · PubMed · Cited by 130
Tian, H., Wittmack, E. K., & Jorgensen, T. J. (2000) · PubMed · Cited by 125
Role of mTOR Signalling in the Control of Translation Initiation and Elongation by Nutrients
Proud, C. G. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_13 · Cited by 122
Growth Signaling: TSC Takes Its Place
Marygold, S. J., & Leevers, S. J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)01294-0 · Cited by 90
Meric‐Bernstam, F. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.10.013 · Cited by 76
Survival pathways meet their end
McCormick, F. P. (2004) · Nature · doi:10.1038/428267a · Cited by 59
Switching from life to death: The Miz-ing link between Myc and p53
Vousden, K. H. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00186-1 · Cited by 56
Weiss, R. H., Marshall, D., Howard, L. L., Corbacho, A. M., Cheung, A., & Sawai, E. T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00495-0 · Cited by 48
Mammalian target of rapamycin (mTOR) inhibitors
Dutcher, J. P. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0022-5 · Cited by 40
mTOR: A Mediator of Intracellular Homeostasis
Jaeschke, A., Dennis, P. B., & Thomas, G. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_17 · Cited by 36
Self-citationGaben, A., Saucier, C., Bedin, M., Barbu, V., & Mešter, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11521 · Cited by 35
Kralj, M., Husnjak, K., Körbler, T., & Pavelić, J. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700588 · Cited by 31
Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance
Ségal-Bendirdjian, E., Mannone, L., & Jacquemin‐Sablon, A. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400357 · Cited by 20
Prendergast, G. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00247-2 · Cited by 14
Cited by
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Metadata
- Authors
- Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 120
- Issue
- 6
- Pages
- 747-759
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2026569756
- Cited by
- 486
- References
- 60
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.